In one embodiment a layered pharmaceutical formulation includes, but is not limited to two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one preferred embodiment at least one of the pharmaceutical layers comprises bupropion. In another preferred embodiment at least one of the pharmaceutical layers comprises zonisamide. In another preferred embodiment at least one of the pharmaceutical layers comprises naltrexone. In another preferred embodiment at least one of the pharmaceutical layers comprises topiramate. In another preferred embodiment at least one of the pharmaceutical layers comprises phentermine. In another preferred embodiment at least one of the pharmaceutical layers comprises metformin. In another preferred embodiment at least one of the pharmaceutical layers comprises olanzapine. In another preferred embodiment at least one of the pharmaceutical layers comprises fluoxetine.在一個實施例中，本發明揭示一種層狀醫藥調配物，其包括(但不限於)兩或多個醫藥層及位於該兩或多個醫藥層中至少兩個層之間的中間層，該中間層係經組構，以便溶解在活體內，藉此使該兩或多個醫藥層實質上保留完好。在一個較佳實施例中，該等醫藥層中至少一層包含安非它酮(bupropion)。在另一較佳實施例中，該等醫藥層中至少一層包含唑尼沙胺(zonisamide)。在另一較佳實施例中，該等醫藥層中至少一層包含納曲酮(naltrexone)。在另一較佳實施例中，該等醫藥層中至少一層包含托吡酯(topiramate)。在另一較佳實施例中，該等醫藥層中至少一層包含芬特明(phentermine)。在另一較佳實施例中，該等醫藥層中至少一層包含二甲雙胍(metformin)。在另一較佳實施例中，該等醫藥層中至少一層包含奧氮平(olanzapine)。在另一較佳實施例中，該等醫藥層中至少一層包含氟西汀(fluoxetine)。
